El libro aborda el uso del radiofármaco 18F-DCFPyL en el diagnóstico de la recidiva bioquímica del cáncer de próstata, destacando su capacidad para unirse al PSMA y ofrecer una detección más sensible y precisa. Se discute su aplicación en España, donde aún no está autorizado para comercialización.
to evaluate the diagnostic utility of 18F-DCFPyL and 18F-Choline PET/CT in prostate cancer patients
The book explores the advancements in prostate cancer diagnosis, particularly the use of fluorine-18 labeled Choline PET/CT and the emerging radiopharmaceutical 18F-DCFPyL. Highlighting the overexpression of Prostate Specific Membrane Antigen (PSMA) in most prostate cancers, it discusses how 18F-DCFPyL offers a potentially more sensitive method for detecting early tumor recurrence. The current status of 18F-DCFPyL in Spain, where it is used in special situations but not yet marketed, underscores the need for further research to establish its diagnostic value.